MBX Biosciences Inc
MBX12.540USD
-1.210-8.80%
收盘 08/04, 16:00（美东）报价延迟15分钟
419.14M总市值
亏损市盈率 TTM
关于 MBX Biosciences Inc 公司
MBX Biosciences, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发用于治疗内分泌和代谢紊乱的新型精准肽疗法。该公司已建立其专有的精准内分泌肽平台，以开发旨在克服当前肽疗法关键限制的精准肽疗法。其候选产品和项目包括 MBX 2109、MBX 1416 和肥胖产品组合。MBX 2109 是一种甲状旁腺激素肽前药，旨在作为一种潜在的长效激素替代疗法，用于治疗慢性甲状旁腺功能减退症。MBX 1416 旨在成为一种长效胰高血糖素样肽-1 (GLP-1) 受体拮抗剂，可作为减肥后低血糖症（减肥手术的慢性并发症）的潜在疗法。 MBX 4291 被设计为长效、高效的 GLP-1 和葡萄糖依赖性胰岛素促泌多肽、受体共激动剂前体药物。
公司简介
公司代码MBX
公司名称MBX Biosciences Inc
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
员工数量43
证券类型Ordinary Share
年结日Sep 13
公司地址11711 N. Meridian Street
城市CARMEL
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编46032
电话13179893100
网址https://mbxbio.com/
公司代码MBX
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. James M. Cornelius
Mr. James M. Cornelius
Independent Director
Independent Director
102.08K
-50.00%
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Ms. Ora Pescovitz, M.D.
Ms. Ora Pescovitz, M.D.
Independent Director
Independent Director
--
--
Mr. Richard B. Bartram, CPA
Mr. Richard B. Bartram, CPA
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. James M. Cornelius
Mr. James M. Cornelius
Independent Director
Independent Director
102.08K
-50.00%
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
17.91%
OrbiMed Advisors, LLC
11.98%
New Enterprise Associates (NEA)
10.81%
Deep Track Capital LP
9.03%
Wellington Management Company, LLP
7.89%
Other
42.38%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
17.91%
OrbiMed Advisors, LLC
11.98%
New Enterprise Associates (NEA)
10.81%
Deep Track Capital LP
9.03%
Wellington Management Company, LLP
7.89%
Other
42.38%
股东类型
持股股东
占比
Private Equity
29.88%
Investment Advisor/Hedge Fund
23.68%
Venture Capital
21.73%
Hedge Fund
18.37%
Investment Advisor
11.45%
Individual Investor
3.12%
Research Firm
1.44%
Sovereign Wealth Fund
0.07%
Bank and Trust
0.05%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
134
36.70M
109.81%
+2.17M
2025Q1
128
36.79M
110.24%
+3.57M
2024Q4
95
34.04M
101.87%
+3.71M
2024Q3
48
31.37M
98.32%
+31.37M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
5.99M
17.91%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
4.00M
11.98%
+190.67K
+5.00%
Mar 31, 2025
New Enterprise Associates (NEA)
3.61M
10.81%
--
--
Mar 31, 2025
Deep Track Capital LP
3.02M
9.03%
--
--
Mar 31, 2025
Wellington Management Company, LLP
2.64M
7.89%
-271.12K
-9.32%
Mar 31, 2025
Norwest Venture Partners
2.14M
6.39%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
1.58M
4.72%
-2.55K
-0.16%
Mar 31, 2025
RA Capital Management, LP
1.51M
4.52%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
1.26M
3.77%
--
--
Mar 31, 2025
MPM BioImpact LLC
1.13M
3.39%
+1.13M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
ALPS Medical Breakthroughs ETF
0.26%
iShares Micro-Cap ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.96%
ALPS Medical Breakthroughs ETF
占比0.26%
iShares Micro-Cap ETF
占比0.04%
Fidelity Enhanced Small Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
